Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

People with neurofibromatosis 1 (NF1) have multiple benign neurofibromas and a 10% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNSTs). Most MPNSTs develop from benign plexiform neurofibromas, so the burden of benign tumors may be a risk factor for developing MPNST. We studied 13 NF1 patients with MPNSTs and 26 age- and sex-matched controls (NF1 patients who did not have MPNSTs) with detailed clinical examinations and whole-body MRI to characterize their body burden of internal benign neurofibromas. Internal plexiform neurofibromas were identified in 22 (56%) of the 39 NF1 patients studied. All six of the NF1 patients with MPNSTs under 30 years of age had neurofibromas visualized on whole-body MRI, compared to only 3 of 11 matched NF1 controls under age 30 (p < 0.05). Both the median number of plexiform neurofibromas (p < 0.05) and the median neurofibroma volume (p < 0.01) on whole-body MRI were significantly greater among MPNST patients younger than 30 years of age than among controls. No significant differences in whole-body MRI findings were observed between NF1 patients with MPNSTs and controls who were 30 years of age or older. Whole-body MRI of NF1 patients allows assessment of the burden of internal neurofibromas, most of which are not apparent on physical examination. Whole-body imaging of young NF1 patients may allow those at highest risk for developing MPNST to be identified early in life. Close surveillance of these high-risk patients may permit earlier diagnosis and more effective treatment of MPNSTs that develop.

[1]  Q. Yang,et al.  Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. , 2001, American journal of human genetics.

[2]  L. Kluwe,et al.  Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors , 2003, Human mutation.

[3]  J. Zeller,et al.  Association between benign and malignant peripheral nerve sheath tumors in NF1 , 2005, Neurology.

[4]  S. Steinberg,et al.  NF1 plexiform neurofibroma growth rate by volumetric MRI , 2007, Neurology.

[5]  R. Hughes,et al.  Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1 , 2000, Journal of neurology, neurosurgery, and psychiatry.

[6]  P. Combemale,et al.  Intérêt de la tomographie par émission de positons au fluorodéoxyglucose 18 dans la détection des neurofibrosarcomes au cours de la neurofibromatose de type 1 , 2007 .

[7]  V. Riccardi.  The genetic predisposition to and histogenesis of neurofibromas and neurofibrosarcoma in neurofibromatosis type 1. , 2007, Neurosurgical focus.

[8]  R. Hughes,et al.  Neurofibromatous neuropathy in neurofibromatosis 1 (NF1) , 2004, Journal of Medical Genetics.

[9]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.

[10]  C. Pratt,et al.  Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution. , 1994, Medical and pediatric oncology.

[11]  R. Siebert,et al.  Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene , 2004, Human mutation.

[12]  B. Fuchs,et al.  Malignant peripheral nerve sheath tumors: an update. , 2005, Journal of surgical orthopaedic advances.

[13]  W. Molenaar,et al.  Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  H. Kehrer-Sawatzki,et al.  High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by somatic recombination of the JJAZ1 gene. , 2004, American journal of human genetics.

[15]  S. Pilotti,et al.  Elevated risk for MPNST in NF1 microdeletion patients. , 2003, American journal of human genetics.

[16]  L. Kluwe,et al.  Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene. , 2005, Anticancer research.

[17]  J. Tonsgard.  Clinical manifestations and management of neurofibromatosis type 1. , 2006, Seminars in pediatric neurology.

[18]  Ziv M. Williams,et al.  Value of PET in the assessment of patients with neurofibromatosis type 1. , 2007, AJR. American journal of roentgenology.

[19]  M. O'Doherty,et al.  [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Ferner.  Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective , 2007, The Lancet Neurology.

[21]  S. Thomson,et al.  Review Article : NF1 Mutations and Molecular Testing , 2002, Journal of child neurology.

[22]  A. Maniker,et al.  Malignant peripheral nerve sheath tumors. , 2007, Neurosurgical focus.

[23]  D. Viskochil.  Review Article : Genetics of Neurofibromatosis 1 and the NF1 Gene , 2002, Journal of child neurology.

[24]  B. Korf,et al.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. , 1997, JAMA.

[25]  V. Mautner,et al.  Spinal tumours in neurofibromatosis type 1: an MRI study of frequency, multiplicity and variety , 1999, Neuroradiology.

[26]  B. Korf.  Review Article : Clinical Features and Pathobiology of Neurofibromatosis 1 , 2002 .

[27]  R. Herva,et al.  Risk of malignancy and death in neurofibromatosis. , 1997, Archives of pathology & laboratory medicine.

[28]  R. Fabrello.  Recommendations for management , 1979 .

[29]  K. Khosrotehrani,et al.  Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients , 2005, American journal of medical genetics. Part A.

[30]  J. Lefaucheur,et al.  Neurofibromatosis 1-associated neuropathies: a reappraisal. , 2004, Brain : a journal of neurology.

[31]  V. Riccardi,et al.  Neurofibromatosis: Phenotype, Natural History and Pathogenesis , 1992 .

[32]  A. Dachman,et al.  CT imaging in adults with neurofibromatosis‐1 , 1998, Neurology.

[33]  R. Buchert,et al.  Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  B. Scheithauer,et al.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases , 1986, Cancer.

[35]  D. Easton,et al.  A prospective study of neurofibromatosis type 1 cancer incidence in the UK , 2006, British Journal of Cancer.

[36]  R. Friedrich,et al.  Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children. , 2007, Anticancer research.

[37]  H. Kehrer-Sawatzki,et al.  Extensively high load of internal tumors determined by whole body MRI scanning in a patient with neurofibromatosis type 1 and a non-LCR-mediated 2-Mb deletion in 17q11.2 , 2005, Human Genetics.